Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSGI for Hypoglycemia Unawareness in T1DM
NCT03490942Phase 2Terminated
- Sponsor
- Xeris Biopharma Holdings, Inc.
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glucagon in Hypoglycemia unawareness (HU) (4 arms), sponsored by Xeris Biopharma Holdings, Inc. Primary endpoint: Plasma Epinephrine Concentration. Started Mar 2018; status: terminated.
02
Drugs
glucagon
03
Conditions
Hypoglycemia unawareness (HU)
Beyond the preview
Go deeper on NCT03490942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490942.